Abbott Laboratories

New York Stock Exchange
Back to all articles
Neutral 0

How The Abbott Laboratories (ABT) Investment Story Is Shifting With New Targets And Trial Updates

AI-generated analysis

📊 Analysts on Abbott are dividing, with Goldman Sachs and Citi maintaining positive ratings but lowering targets while Bernstein lifted its target to US$154.

⚖️ A broad group of banks including Barclays, Evercore ISI, Wells Fargo, Oppenheimer, and others have cut price targets in recent months due to increased scrutiny on earnings and pipeline execution.

🔍 January saw multiple reductions of over US$10 from firms like Bernstein and Wells Fargo, signaling reassessment of growth assumptions and delivery risks despite constructive ratings.

💰 The Fair Value for Abbott Laboratories has been reset downward from US$132.64 to US$131.44 based on updated valuation models.

📈 Revenue growth assumptions have increased significantly from 7.86% to 10.24%.

📉 Net profit margin estimates have been revised downward from 17.96% to 15.60%.

🔒 Valuation multiples for future earnings were adjusted upward slightly, with the target P/E multiple shifting from 28.84x to 30.91x.

🏥 Abbott is integrating its Precision Oncology tests, including Oncotype DX and OncoExTra, directly into Flatiron Health's workflow to serve over 1,600 U.S. cancer centers.

🩸 New FreeDM2 trial data show the FreeStyle Libre continuous glucose monitoring system delivered a 0.6% greater HbA1c reduction compared with traditional fingersticks.

❤️ Abbott reported positive clinical results for its Volt Pulsed Field Ablation System and TactiFlex Duo Ablation Catheter, achieving high success rates in treating paroxysmal AFib.

⚠️ A wrongful death lawsuit was filed against Abbott over alleged defects in FreeStyle Libre sensors that are linked to seven deaths globally and numerous serious injuries.

📉 The company recently faced FDA recalls and a medical device correction affecting approximately 3,000,000 sensors in the U.S. due to accuracy issues.

🌎 Long-term investment narratives link Abbott's growth to demand from emerging markets, an expanding middle class, and aging populations driving its portfolio of branded generics and biosimilars.

🩺 Medical technology products, specifically FreeStyle Libre and structural heart management devices, are seen as key drivers supporting the long-term earnings story.

⚠️ Key risks facing the stock include pricing pressure in diagnostics and CGM sectors, exposure to tariffs and forex fluctuations, tighter regulation, and ongoing litigation.

Bullish Signals
  • Several firms including Goldman Sachs and Citi maintain positive ratings on Abbott Laboratories while fine-tuning price targets, signaling confidence in the business fundamentals despite recalibrations.
  • Bernstein recently lifted its price target to US$154, highlighting healthy sector fundamentals in medical technology and continued strong investor interest in major healthcare names like Abbott.
  • Abbott's integration of Precision Oncology tests into Flatiron Health is expanding access, allowing over 1,600 U.S. community cancer centers and 4,700 providers to order results directly within existing workflows.
  • New FreeDM2 trial data show that patients using the FreeStyle Libre continuous glucose monitoring system experienced a 0.6% greater HbA1c reduction and spent 2.5 more hours per day in a healthy glucose range compared with traditional fingersticks.
  • Abbott's Volt Pulsed Field Ablation System reported an 84.2% freedom from rhythm recurrence in paroxysmal AFib, while the TactiFlex Duo Ablation Catheter showed an 81% success rate for similar cases.
  • FDA approval, CE Mark and Breakthrough Device Designation have been granted for related programs supporting Abbott's structural heart and rhythm management portfolio.
  • Analyst forecasts show revised revenue growth assumptions increased from 7.86% to 10.24%, reflecting optimistic long-term earnings expectations.
  • The Future P/E target multiple was adjusted upward from 28.84x to 30.91x, indicating a higher valuation multiple expected by analysts despite margin revisions.
Risk Factors
  • A wrongful death lawsuit has been filed against Abbott over alleged defects in FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors.
  • The lawsuit cites links to seven deaths globally, about 800 reports of serious injury and a prior medical device correction affecting about 3,000,000 sensors in the U.S.
  • Earlier FDA classified recalls tied to accuracy issues have added to the regulatory concerns surrounding the FreeStyle Libre sensor line.
  • A broad group of banks, including Barclays, Evercore ISI, Wells Fargo, Oppenheimer, Citi, Mizuho, Piper Sandler and BTIG, has cut price targets in recent months.
  • Multiple US$10 plus target reductions on a single day in January from firms such as Bernstein and Wells Fargo show that analysts are reassessing growth assumptions.
  • Net profit margin was revised down from 17.96% to 15.60%, indicating reduced profitability expectations despite revenue growth assumptions being increased.
  • Fair value was reset from US$132.64 to US$131.44, reflecting a lower valuation multiple in light of new risks and competitive scrutiny.
Full Analysis
Abbott Laboratories is currently experiencing a shift in investor sentiment as analysts revise price targets following new research and trial updates, creating a debate over valuation despite the company's fundamental strength. While Goldman Sachs and Citi maintain positive ratings by fine-tuning their models, there is significant divergence among major banks; institutions like Bernstein recently lifted its target to US$154 citing healthy sector fundamentals, whereas a broad group including Barclays, Evercore ISI, Wells Fargo, and Oppenheimer have cut targets in recent months. This clustering of revisions around the mid-US$150s reflects increased scrutiny on earnings and pipeline execution, highlighted by multiple firms reducing their targets by more than US$10 in January alone as analysts reassess growth assumptions and risks related to Abbott's ability to deliver on its plans. The underlying business narrative continues to evolve alongside positive operational developments and emerging clinical data. Abbott is integrating its Precision Oncology tests into Flatiron Health's OncoEMR platform, which could allow over 1,600 U.S. community cancer centers to utilize results within existing workflows. Furthermore, new FreeDM2 trial data from the FreeStyle Libre continuous glucose monitoring system showed a 0.6% greater HbA1c reduction compared with traditional fingersticks, while reported data for Volt and TactiFlex Duo ablation catheters demonstrated high success rates in treating paroxysmal atrial fibrillation alongside recent regulatory approvals. These advancements support the long-term earnings story tied to medical technologies and structural heart devices. However, these positive developments are offset by significant legal and valuation risks. A wrongful death lawsuit has been filed against Abbott regarding alleged defects in FreeStyle Libre 3 sensors, citing links to seven deaths globally and approximately 800 reports of serious injury following a prior FDA classified recall affecting about 3 million sensors. These risks have prompted a reset in financial valuations and assumptions provided by Simply Wall St, with fair value adjusted down from US$132.64 to US$131.44, net profit margin revised downward from 17.96% to 15.60%, and revenue growth expectations increased from 7.86% to 10.24%. Ultimately, the investment thesis for Abbott now balances strong medical technology innovations against regulatory scrutiny, litigation costs, and potential pricing pressures in diagnostics.